What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?
What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?
Additionally, the analyst's dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.On Wednesday, Patient Square Capital, a healthcare investment firm, agreed to acquire Patterson Companies, Inc. (NASDAQ:PDCO), a dental and animal health product distributor, for approximately $4.1 billion.
在週三，醫療投資公司Patient Square Capital同意收購帕特森公司（納斯達克：PDCO），這是一家牙科和動物健康產品分銷商，交易金額約爲41億美金。
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger, to boost shareholder value.
在其第二季度盈利報告中，公司宣佈正在探索戰略選擇，包括出售或合併，以提升股東價值。
William Blair notes that based on Patient Square Capital's portfolio, which doesn't include dental or animal health companies, regulatory hurdles for this deal are unlikely.
William Blair指出，基於Patient Square Capital的投資組合，其中不包括牙科或動物健康公司，因此該交易的監管障礙不太可能出現。
Additionally, the analyst's dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
此外，分析師的牙科估值分析表明，帕特森的報價強勁，因此在40天的競爭性報價窗口期內不太可能出現更高的出價。
The valuation analysis includes Align Technology Inc (NASDAQ:ALGN), Dentsply Sirona Inc (NASDAQ:XRAY), Henry Schein Inc (NASDAQ:HSIC), Envista Holdings Corporation (NYSE:NVST) and Europe-listed Straumann Holding.
該估值分析包括Align Technology Inc（納斯達克：ALGN）、登士柏公司（納斯達克：XRAY）、漢瑞祥公司（納斯達克：HSIC）、Envista Holdings Corporation（紐交所：NVST）和在歐洲上市的Straumann Holding。
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
William Blair寫道，他們關注的大多數牙科公司交易價格已接近15年來的最低估值，因投資者興趣因持續的宏觀經濟挑戰而下降。
Most recently, Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary suspension of sales, marketing, and shipments of Byte Aligners and Impression Kits.
最近，登士柏修訂了其2024年展望，原因是市場壓力影響美國設備，立法變化影響直接面向消費者的矯正器商業模式，以及自願暫停Byte Aligners和印象工具的銷售、市場推廣和發貨。
Henry Schein's third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) to $1.1 billion.
漢瑞祥第三季度全球牙科部門銷售額爲19億美金，下降了1.6%，醫療部門銷售額增長了2.9%（內部下降4.8%），達到了11億美金。
While it's still early to gauge investor reactions, the analyst is considering whether Patterson's acquisition might stabilize valuations and boost demand in the dental sector.
雖然現在還早，無法評估投資者的反應，但分析師正在考慮帕特森的收購是否可能穩定估值並提升醫療板塊的需求。
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
分析師寫道，此舉可能支持估值，並暗示市場的潛在復甦，使得許多醫療股票在風險/回報方面變得更加吸引人。
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
在這些股票中，威廉·布萊爾認爲Align具有最大的股票增長潛力，得益於市場條件的改善以及收益和估值的增長。
- Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details
- Gevo與LG化學在乙醇轉烯烴技術方面加大投入：詳情
Photo via Shutterstock
圖片來自shutterstock
譯文內容由第三人軟體翻譯。
